0001493152-24-005079.txt : 20240206
0001493152-24-005079.hdr.sgml : 20240206
20240206151632
ACCESSION NUMBER: 0001493152-24-005079
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240202
FILED AS OF DATE: 20240206
DATE AS OF CHANGE: 20240206
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Raines Heather
CENTRAL INDEX KEY: 0001770650
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36457
FILM NUMBER: 24599850
MAIL ADDRESS:
STREET 1: 10025 INVESTMENT DRIVE
STREET 2: SUITE 250
CITY: KNOXVILLE
STATE: TN
ZIP: 37932
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: PROVECTUS BIOPHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0000315545
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 900031917
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 800 S. GAY STREET
STREET 2: SUITE 1610
CITY: KNOXVILLE
STATE: TN
ZIP: 37929
BUSINESS PHONE: (866) 594-5999
MAIL ADDRESS:
STREET 1: 800 S. GAY STREET
STREET 2: SUITE 1610
CITY: KNOXVILLE
STATE: TN
ZIP: 37929
FORMER COMPANY:
FORMER CONFORMED NAME: PROVECTUS PHARMACEUTICALS INC
DATE OF NAME CHANGE: 20020417
FORMER COMPANY:
FORMER CONFORMED NAME: ZAMAGE DIGITAL IMAGING INC
DATE OF NAME CHANGE: 20011126
FORMER COMPANY:
FORMER CONFORMED NAME: SPM GROUP INC
DATE OF NAME CHANGE: 19920703
4
1
ownership.xml
X0508
4
2024-02-02
0
0000315545
PROVECTUS BIOPHARMACEUTICALS, INC.
PVCT
0001770650
Raines Heather
800 S. GAY STREET, SUITE 1610
KNOXVILLE
TN
37929
0
1
0
0
CFO
0
8% Unsecured Convertible Promissory Note due 2022
2.862
2024-02-02
4
D
0
25000
25000
D
2021-08-16
2023-08-16
Series D-1 Convertible Preferred Stok
8736
175000
D
On February 2, 2024, the Issuer repaid $25,000 of the amount outstanding under the 8% unsecured convertible promissory note due 2022 (the "Note").
The Reporting Person may elect to convert the outstanding principal and interest of the Note as follows: (i) the Note is convertible into shares of Series D-1 Convertible Preferred Stock, par value $0.001 per share ("Series D-1 Preferred Stock") at a price per share equal to $2.862; (ii) in the event the Issuer conducts a qualified equity financing in the aggregate amount of $20 million, the Note is convertible into the shares of capital stock being issued by the Issuer in such qualified equity financing at the price per share being paid by the investors in such qualified equity financing; and (iii) in the event the Issuer conducts a qualified debt financing with more favorable terms than the Note in the aggregate amount of $20 million, the Note may be exchanged for the debt instrument being issued by the Issuer in such qualified debt financing.
Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"). The Series D-1 Preferred Stock will automatically convert into Common Stock on June 20, 2026, unless earlier converted into Common Stock in accordance with the terms of the Certificate of Designation for the Series D-1 Preferred Stock.
/s/ Heather Raines
2024-02-06